Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis

Reproductive Sciences

Volumn 22, Issue 6, 2015, Pages 679-684

  Farahani, Maryam Shahrabi ^a   Shahbazi, Shirin ^b   Moghaddam, Soheila Amini ^b   Mahdian, Reza ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

cell free DNA; endometriosis; KRAS gene; let 7 microRNA; single nucleotide polymorphism

Indexed keywords

BIOLOGICAL MARKER; DNA; GENOMIC DNA; K RAS PROTEIN; MESSENGER RNA; 3' UNTRANSLATED REGION; KRAS PROTEIN, HUMAN; MICRORNA; MIRNLET7 MICRORNA, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ADULT; ARTICLE; BINDING SITE; CASE CONTROL STUDY; CELL FREE SYSTEM; CONTROLLED STUDY; DNA ISOLATION; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; 3' UNTRANSLATED REGION; GENETIC PREDISPOSITION; GENETICS; IRAN; METABOLISM; MIDDLE AGED; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; UPREGULATION;

3' UNTRANSLATED REGIONS; ADULT; BINDING SITES; CASE-CONTROL STUDIES; CELL-FREE SYSTEM; ENDOMETRIOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MICRORNAS; MIDDLE AGED; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; UP-REGULATION;

EID: 84930813113     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114556478     Document Type: Article

References (19)

1. Benagiano G, Brosens I. The history of endometriosis: identifying the disease. Hum Reprod. 1991 ; 6 (7). 963-968
2. Giudice LC, Kao LC. Endometriosis. Lancet. 2004 ; 364 (9447). 1789-1799
3. Allaire C. Endometriosis and infertility: a review. J Reprod Med. 2006 ; 51 (3). 164-168
4. Matalliotakis IM, Arici A, Cakmak H, et al. Familial aggregation of endometriosis in the Yale Series. Arch Gynecol Obstet. 2008 ; 278 (6). 507-511
5. Kao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003 ; 144 (7). 2870-2881
6. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005 ; 11 (1). 63-70
7. Afshar Y, Hastings J, Roqueiro D, Jeong JW, Giudice LC, Fazleabas AT. Changes in eutopic endometrial gene expression during the progression of experimental endometriosis in the baboon. Papio anubis Biol Reprod. 2013 ; 88 (2). 44
8. Vercellini P, Trecca D, Oldani S, Fracchiolla NS, Neri A, Crosignani PG. Analysis of p53 and ras gene mutations in endometriosis. Gynecol Obstet Invest. 1994 ; 38 (1). 70-71
9. Zhao ZZ, Nyholt DR, Le L, et al. KRAS variation and risk of endometriosis. Mol Hum Reprod. 2006 ; 12 (11). 671-676
10. Grechukhina O, Petracco R, Popkhadze S, et al. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med. 2012 ; 4 (3). 206-217
11. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008 ; 68 (20). 8535-8540
12. Ratner E, Lu L, Boeke M, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010 ; 70 (16). 6509-6515
13. Pharoah PD, Palmieri RT, Ramus SJ, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 2011 ; 17 (11). 3742-3750
14. Cerne JZ, Stegel V, Gersak K, Novakovic S. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer. 2012 ; 12: 105
15. Lee LJ, Ratner E, Uduman M, et al. The KRAS-variant and miRNA expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLoS One. 2014 ; 9 (4). e94167
16. Luong HT, Nyholt DR, Painter JN, et al. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis. Hum Reprod. 2012 ; 27 (12). 3616-3621
17. Zachariah R, Schmid S, Radpour R, et al. Circulating cell-free DNA as a potential biomarker for minimal and mild endometriosis. Reprod Biomed Online. 2009 ; 18 (3). 407-411
18. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med. 2010 ; 10 (2). 142-165
19. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011 ; 223 (2). 219-229